Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension, Cardiovascular Diseases, Cardiovascular Risk Factors, Circadian Rhythms, Sleep
Interventions: At-home Polysomnography, Circadian Protocol, Rested Wakefulness Trial, Overnight Sleep Trial, Regularized Sleep Schedule; Other · Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 25 Years to 64 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hypertension
Interventions: Anti-hypertensive therapy, No anti-hypertensive therapy (unless BP is severe); Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 12 Years and older · Female only
Enrollment: 2,408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 72
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Beraprost sodium modified release; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Torrance, California • Pittsburgh, Pennsylvania • Dallas, Texas

Conditions: Chronic Disease, Diabetes Mellitus, Hypertension, Congestive Heart Failure
Interventions: Social Risk Score and CDS Tool, Standard of Care; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Baltimore, Maryland

Conditions: Glaucoma and Ocular Hypertension
Interventions: DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost, Placebo; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 10
States / cities: Newport Beach, California • Deerfield Beach, Florida • Largo, Florida + 7 more

Conditions: Anemia in Pregnancy, Preeclampsia
Interventions: Neevo® (a medical food), Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12); Other
Lead sponsor: Pamlab, Inc.; Industry
Eligibility: 21 Years to 39 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Sheffield, Alabama • Flowood, Mississippi • Gainesville, Texas

Conditions: Hypertension
Interventions: Amlodipine/benazepril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 275 participants
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension
Interventions: Metoprolol, Chlorthalidone; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 839 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Gainesville, Florida • Atlanta, Georgia • Rochester, Minnesota

Conditions: Cirrhosis, Liver, Hypertension, Portal, Esophageal and Gastric Varices, Bleeding Gastric, Encephalopathy
Interventions: TIPS-obliteration; Device
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atherosclerosis, High Blood Pressure, Type 2 Diabetes Mellitus, Heart Disease, Hypercholesterolemia
Interventions: Special Intervention; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 40 Years and older
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Hypertension, Left Ventricular Hypertrophy
Interventions: Eplerenone, Chlorthalidone, Potassium; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Azilsartan medoxomil and chlorthalidone, Chlorthalidone, Azilsartan medoxomil; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 84
States / cities: Birmingham, Alabama • Columbiana, Alabama • Tuscaloosa, Alabama + 81 more

Conditions: Open Angle Glaucoma
Interventions: Goniotomy, Trabecular Micro-Bypass Stent, Cataract Extraction; Procedure · Device
Lead sponsor: New World Medical, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: La Crosse, Wisconsin

Conditions: Pulmonary Arterial Hypertension
Interventions: Shape II CPET; Device
Lead sponsor: Shape Medical Systems, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 6
States / cities: Torrance, California • Denver, Colorado • Jacksonville, Florida + 3 more

Conditions: Pre-Eclampsia, Gestational Hypertension, Sleep
Interventions: SNOO, Safe sleep education in the postpartum period; Device · Other
Lead sponsor: Alisse Hauspurg; Other
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension
Interventions: Irbesartan and Hydrochlorothiazide, Avalide; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Preeclampsia, Preeclampsia Severe, Gestational Hypertension, Hypertensive Disorder of Pregnancy, Superimposed Pre-Eclampsia
Interventions: Nudge; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: Optical Blood Pressure Monitoring Device (Aktiia G1); Device
Lead sponsor: Nucor; Industry
Eligibility: 25 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Glaucoma
Interventions: 0.005% Latanoprost dosed once.; Drug
Lead sponsor: Nanduri, Padma, M.D., FACS; Individual
Eligibility: 21 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Visalia, California

Conditions: Overweight or Obesity, Prediabetes or Diabetes, Prehypertension (Elevated Blood Pressure) or Hypertension, Resistance Training
Interventions: Resistance Training; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 30 Years to 64 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypertension
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 30 Years to 55 Years
Enrollment: 1,692 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ocular Hypertension, Primary Open-Angle Glaucoma
Interventions: AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3, AGN-210961 Formulation 4, AGN-210961 Formulation 5, AGN-210961 Formulation 6, AGN-210961 Formulation 7, bimatoprost ophthalmic solution 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Salt Sensitivity of Blood Pressure, Hypertension
Interventions: High Salt Diet, Low Salt Diet; Dietary Supplement
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 50 Years to 70 Years
Enrollment: 281 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Birmingham, Alabama • Chicago, Illinois

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: Brimonidine purite 0.15%, Dorzolamide 2%, Brinzolamide 1%; Drug
Lead sponsor: Northwestern Ophthalmic Institute S.C.; Other
Eligibility: 41 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Glenview, Illinois

Search by objective public record fields.

Sleep and Circadian Mechanisms in Hypertension

Chronic Hypertension and Pregnancy (CHAP) Project

A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients

Social Risk Score, Clinical Decision Support Tool and Closed Loop Referral for Social Risk Screen and Referral

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

A Retrospective Analysis of Neevo®/Neevo®DHA Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy

Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus

Pharmacogenomic Evaluation of Antihypertensive Responses 2

TIPS Plus Transvenous Obliteration for Gastric Varices

Latinos Understanding the Need for Adherence

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension

A Comparison of Two Ab Interno Procedures in the Treatment of Glaucoma in Patients Undergoing Cataract Extraction

Assessing the Utility of Submaximal CPET in Treatment Management of PAH

Neonatal Sleep Intervention to Improve Postpartum Hypertension

Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions

Nudge to Drive Transitions of Care

A Comprehensive Optical Blood Pressure Assessment Tool to Identify Cases of Unscreened Hypertension Across an Active Population in the U.S.

Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy

Remotely Delivered Resistance Training for Cardiometabolic Health Among Black Women

Minority Health Genomics and Translational Research Bio-Repository Database (MH-GRID)-2.0

Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

CARDIA-Salt Sensitivity of Blood Pressure (SSBP)

Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs